10-Q: Climb Bio Reports Q3 2025 Loss, Advances Pipeline

Climb Bio, Inc. reported a net loss of $12.9 million for Q3 2025, while advancing its lead product candidates budoprutug and CLYM116 in clinical trials.

Summary

• Net loss for the three months ended September 30, 2025, was $12.9 million, compared to $8.9 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $42.3 million, a reduction from $65.5 million for the same period in 2024.
• Research and development (R&D) expenses increased to $9.1 million for Q3 2025 from $6.2 million for Q3 2024, driven by budoprutug program advancement and CLYM116 licensing/manufacturing costs.
• Cash, cash equivalents, and marketable securities totaled $175.8 million as of September 30, 2025.
• Existing capital is estimated to be sufficient to fund operations through 2027.
• Budoprutug is progressing in Phase 2 for primary membranous nephropathy (pMN), Phase 1b/2a for immune thrombocytopenia (ITP), and Phase 1b for systemic lupus erythematosus (SLE).
• Long-term follow-up data from a previous Phase 1b budoprutug trial in pMN showed proteinuria control for up to three years in four patients, with three requiring no further immunosuppressive treatment.
• A Phase 1 clinical trial for a subcutaneous (SC) formulation of budoprutug in healthy volunteers is actively enrolling and dosing in Australia.
• CLYM116, an anti-APRIL monoclonal antibody for immunoglobulin A nephropathy (IgAN), reported preclinical data demonstrating improved bioavailability, prolonged exposure, and deeper IgA reduction compared to sibeprenlimab.
• A Phase 1 clinical trial for CLYM116 in healthy volunteers in Australia is expected to dose its first subject by year-end 2025.
• Material weaknesses in internal control over financial reporting remain unremediated as of September 30, 2025.

Sentiment

Score: 6

Explanation: The company shows promising clinical progress in a competitive field with a decent cash runway, but significant losses and unremediated internal control weaknesses present considerable risks. The sentiment is neutral to slightly positive, reflecting the mixed signals and the need for further clarity on financial stability and successful clinical outcomes.

Positives

• Budoprutug is advancing into a Phase 2 clinical trial (PrisMN) for primary membranous nephropathy (pMN), with the first patient expected to be dosed in the coming weeks.
• Positive long-term follow-up clinical data from a previously conducted Phase 1b trial of budoprutug in pMN demonstrated long-term control of proteinuria for up to three years in four patients, with three patients requiring no further immunosuppressive treatment.
• Budoprutug has received Orphan Drug Designation from the FDA for the treatment of pMN.
• Initiated Phase 1b/2a clinical trial of budoprutug in immune thrombocytopenia (ITP) and Phase 1b clinical trial of budoprutug in systemic lupus erythematosus (SLE), with regulatory clearance in multiple countries.
• Advancing a subcutaneous (SC) formulation of budoprutug, with non-clinical data showing high bioavailability and favorable tolerability, and a Phase 1 clinical trial initiated in Australia.
• CLYM116 preclinical data demonstrated improvement over sibeprenlimab, including high bioavailability, approximately two to three times longer half-life, and deeper and more prolonged IgA reduction.
• Received CTA clearance for a Phase 1 clinical trial of CLYM116 in healthy volunteers in Australia, with the first subject expected to be dosed by year-end 2025.
• Estimated cash, cash equivalents, and marketable securities of $175.8 million as of September 30, 2025, are believed to be sufficient to fund operations through 2027.
• Net loss for the nine months ended September 30, 2025, decreased to $42.3 million from $65.5 million in the prior year period.

Negatives

• Incurred a net loss of $12.9 million for the three months ended September 30, 2025, an increase from $8.9 million in the prior year period.
• Accumulated deficit reached $272.2 million as of September 30, 2025.
• No product revenue has been generated since inception, and no products are approved for sale.
• Anticipates incurring substantial operating losses for the foreseeable future.
• Material weaknesses in internal control over financial reporting identified in 2020 remain unremediated as of September 30, 2025.
• Cash and cash equivalents decreased significantly from $87.2 million at December 31, 2024, to $25.8 million at September 30, 2025.
• Research and development expenses increased to $33.0 million for the nine months ended September 30, 2025, from $8.4 million in the prior year period, reflecting increased program costs.

Risks

• Incurred significant losses since inception and anticipates substantial losses for the foreseeable future, potentially never achieving or maintaining profitability.
• Inability to access capital when needed could force delays, reductions, or termination of product development programs, commercialization efforts, or other operations.
• Future success is dependent primarily on the regulatory approval and commercialization of product candidates, budoprutug and CLYM116.
• Estimates of market opportunity and forecasts of market growth for product candidates may prove inaccurate.
• Preliminary, initial, or interim results from clinical trials may change as more data and information become available, potentially altering final trial results.
• Preclinical and clinical development is a lengthy, complex, and expensive process with an uncertain outcome, and early trial results may not predict success in later trials.
• Faces significant competition in an environment of rapid technological change, with competitors potentially achieving regulatory approval first or developing superior therapies.
• Relies on third parties to conduct, supervise, and monitor preclinical studies and clinical trials; failure of these third parties could prevent regulatory approval or commercialization.
• Contracts with third parties, including single-source suppliers and manufacturers, for critical materials, increasing the risk of supply disruptions or unacceptable costs.
• Compromised or interrupted information technology systems or data, or those of third parties, could lead to adverse consequences including regulatory investigations, litigation, fines, and reputational harm.
• Relies heavily on certain in-licensed patents and other intellectual property rights and may need to acquire or license additional rights.
• Cannot assure that current or future patent applications will result in issued patents, and inability to obtain, maintain, and protect sufficient intellectual property rights could harm competitiveness.
• Identified material weaknesses in internal control over financial reporting; inability to remediate or future weaknesses could adversely affect accurate and timely financial reporting.
• The trading price of common stock has been and may continue to be volatile, potentially leading to substantial losses for purchasers.
• May be required to make significant payments (milestones, royalties) in connection with license agreements.
• Product candidates may cause adverse events and/or undesirable side effects, potentially delaying or preventing regulatory approval or limiting commercial profile.
• Difficulties enrolling and/or retaining patients in clinical trials could delay or adversely affect clinical development activities.
• Could be subject to product liability lawsuits based on the use of product candidates.
• Disruptions at the FDA and other government agencies (e.g., funding cuts, personnel losses, government shutdowns) could hinder timely guidance and approval.
• Enacted and future legislation (e.g., ACA, IRA, OBBBA) may increase the difficulty and cost of obtaining marketing approval and commercialization, and affect product pricing.
• Business operations and relationships with healthcare professionals are subject to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare regulations; non-compliance could lead to substantial penalties.
• Subject to stringent and evolving U.S. and foreign laws, regulations, and contractual obligations related to data privacy and security; failure to comply could lead to regulatory actions, litigation, fines, and business disruptions.
• May not receive Breakthrough Therapy, Fast Track, Priority Review, or PRIME designations, or such designations may not lead to faster development or regulatory review.
• Accelerated approval, even if granted, may not lead to faster development or regulatory review and does not increase the likelihood of full marketing approval, and approval could be withdrawn.
• May be unable to realize the benefits associated with orphan drug designation, including market exclusivity.
• Product candidates regulated as biologics, if approved, may face competition from biosimilars.
• The FDA may not accept data from clinical trials conducted outside the U.S., leading to additional delays and expense.
• Inability to protect intellectual property rights throughout the world.
• May not identify relevant third-party patents or may incorrectly interpret their relevance, scope, or expiration, adversely affecting ability to develop and market product candidates.
• Failure to comply with obligations in license agreements could lead to loss of license rights important to the business.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time.
• Changes in patent law could diminish the value of patents.
• Reliance on third parties requires sharing trade secrets, increasing the possibility of discovery or misappropriation.
• May become involved in lawsuits to protect or enforce patents or other intellectual property, which could be expensive, time-consuming, and unsuccessful.
• Inability to protect the confidentiality of trade secrets would harm business and competitive position.
• May not be able to protect and enforce trademarks and trade names or build name recognition.
• Intellectual property rights do not necessarily address all potential threats.
• Failure to attract and retain management and other key personnel could impede successful development or commercialization.
• Employees, independent contractors, consultants, and other third parties may engage in misconduct or other improper activities.
• International operations expose the company to business, regulatory, political, operational, financial, pricing, and reimbursement risks.
• May not be able to utilize a significant portion of net operating loss carryforwards due to ownership changes.
• Failure to manage acquisitions, investments, licenses, or other strategic alliances could have a material adverse effect on operating results.
• Broad discretion in the use of cash, cash equivalents, and marketable securities, which may not be used effectively.
• A significant portion of common stock may be sold into the market, potentially causing the market price to drop significantly.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Claims for indemnification by directors and officers may reduce available funds.
• Concentration of ownership of common stock among existing executive officers, directors, and principal stockholders may limit new investors from influencing significant corporate decisions and reduce public float.
• Unfavorable global economic conditions could adversely affect business, financial condition, stock price, and results of operations.
• As an emerging growth company and a smaller reporting company, reduced reporting requirements may make common stock less attractive to investors.
• May be unable to maintain adequate insurance coverage.
• Changes in tax laws or regulations that are applied adversely may seriously harm the business.

Future Outlook

The company expects to incur substantial expenses and operating losses for the foreseeable future as it advances its product candidates and expands corporate infrastructure. Existing cash, cash equivalents, and marketable securities are estimated to fund operations through 2027, but substantial additional financing will be needed thereafter. Initial clinical data for the subcutaneous formulation of budoprutug is expected in the first half of 2026, and initial data for budoprutug in ITP and SLE is anticipated in the second half of 2026. The first subject in the CLYM116 Phase 1 trial is expected to be dosed by year-end 2025, with initial clinical data anticipated in mid-2026. The Kv7 program is being evaluated for potential partnership.

Management Comments

• "We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for the millions of patients living with immune-mediated diseases."
• "We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development paths and have the potential to address significant unmet needs."
• "We believe we are well-positioned to advance budoprutug across three distinct opportunity sets in immune-mediated disease: primarily IgG4-mediated diseases, primarily single organ IgG1-3 mediated diseases and complex systemic diseases."
• "We expect to have initial data, including preliminary efficacy, from the Phase 1b/2a clinical trial in ITP in the second half of 2026."
• "We expect to have initial data, including preliminary efficacy, from the Phase 1b clinical trial in SLE in the second half of 2026."
• "We are actively enrolling and dosing subjects in this trial [SC budoprutug Phase 1] and expect to have initial clinical data in the first half of 2026."
• "We expect to dose the first subject [CLYM116 Phase 1] by year-end 2025 and anticipate having initial clinical data from the Phase 1 trial in mid-2026."
• "We believe our available cash, cash equivalents and marketable securities of $175.8 million as of September 30, 2025 will be sufficient to meet its projected operating requirements for at least the next twelve months from the filing date of these unaudited condensed consolidated financial statements, and the Company anticipates that it will need to raise substantial financing in the future to fund its operations."
• "Management has concluded that the material weaknesses in internal control over financial reporting were due to the fact that we were a private company with limited resources when the material weaknesses were identified for the year ended December 31, 2020, and did not have the necessary business processes and related internal controls formally designed and implemented, coupled with the appropriate resources with the appropriate level of experience and technical expertise, to oversee our business processes and controls."

Industry Context

The company operates in the highly competitive biotechnology industry, specifically targeting immune-mediated diseases, a field characterized by rapid technological change and a strong emphasis on intellectual property. The competitive landscape for its lead product candidate, budoprutug (anti-CD19 mAb), includes major pharmaceutical and biotech companies developing various CD19-targeting therapies, such as Amgen, Eli Lilly, AbbVie, Cullinan Therapeutics, Zenas BioPharma, Roche, Merck, and several CAR-T/CAR-NK developers. For CLYM116 (anti-APRIL mAb), competitors include Otsuka (with sibeprenlimab, which CLYM116 preclinical data suggests it improves upon), Novartis, Jade Biosciences, Vertex Pharmaceuticals, Vera Therapeutics, Biogen, Takeda Pharmaceuticals, and Biohaven. The industry faces increasing legislative and regulatory scrutiny, particularly regarding drug pricing (e.g., Inflation Reduction Act, One Big Beautiful Bill Act, MFN pricing proposals) and evolving data privacy laws (e.g., GDPR, CCPA, Data Security Program Rule). Disruptions at regulatory agencies, such as the FDA, due to funding cuts or personnel changes, also pose a risk to development and approval timelines across the sector.

Comparison to Industry Standards

• For budoprutug (anti-CD19 mAb), competitors include Amgen (UPLIZNA for neuromyelitis optica spectrum disorder and IgG4-related disease, BLA filed for generalized myasthenia gravis), IASO Biotherapeutics (RD129/IASO782 in Phase 1 for autoimmune disease), Eli Lilly (LY-3541860, a non-depleting CD19-targeted antibody), and AbbVie (ABBV-319, a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate).
• Other competitors in the CD19-targeting space include Cullinan Therapeutics (CLN-978), Zenas BioPharma (obexelimab), Roche (RG6382), and Merck (CN201) developing bispecific T-cell engagers, as well as Novartis, Bristal Meyers Squibb, Cabaletta Bio, Kyverna Therapeutics, and Nkarta developing CAR-T and CAR-NK therapies.
• For CLYM116 (anti-APRIL mAb), competitors include Otsuka (sibeprenlimab, with a BLA filed), Novartis (zigakibart), Jade Biosciences (JADE-101), Vertex Pharmaceuticals (povetacicept), and Vera Therapeutics (atacicept) targeting APRIL or BAFF/APRIL.
• Additional competitors for IgAN include Biogen (felzartamab) and Takeda Pharmaceuticals (mezagitamab) targeting CD38, and Biohaven (BHV-1400) developing degraders.
• The company's preclinical data for CLYM116 demonstrated improvement over sibeprenlimab, including higher bioavailability, prolonged exposure (approximately two to three times longer half-life), and deeper and more prolonged IgA reduction, suggesting a potentially differentiated profile against an advanced competitor.
• The company's recurring losses and need for future financing are common for early-stage biotechnology companies focused on R&D, but the unremediated material weaknesses in internal control over financial reporting are a notable deviation from expected governance standards for a publicly traded entity.

Corporate Governance

Legal Proceedings

• Not party to any material legal matters or claims as of the date of filing.
• May become involved in securities litigation or stockholder derivative litigation in connection with the Acquisition and related private placement.
• The company's ability to develop and market new product candidates may be impacted by broader industry litigation challenging FDA approvals, such as the ongoing mifepristone case, which could introduce regulatory uncertainty and delays.
• The company is monitoring litigation related to the Inflation Reduction Act (IRA) and other drug pricing policies, which could affect future revenues and business operations.

Related Party Transactions

• The acquisition of Tenet Medicines, Inc. on June 27, 2024, was a related party transaction as Tenet was majority-owned by funds affiliated with RA Capital Management, L.P., which beneficially owned approximately 43.9% of Climb Bio's common stock prior to the acquisition.
• The private placement of 31,238,282 shares of common stock in June 2024, generating $120.0 million gross proceeds, included funds affiliated with RA Capital Management, L.P. as PIPE Investors.
• An acquired in-process research and development expense of $51.7 million was recognized for the nine months ended September 30, 2024, related to the Tenet acquisition from a related party.
• The Mabworks Agreement, entered into on January 8, 2025, for CLYM116 rights, involves Mabworks, a Chinese corporation, and includes collaboration on global clinical studies and rights in Greater China.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises and stock price volatility. The concentration of ownership by existing executive officers, directors, and principal stockholders (e.g., RA Capital Management, L.P. owning 46.1%) may limit the influence of new investors.
• Employees benefit from equity compensation plans (2019, 2021 Equity Incentive Plans, 2025 Inducement Plan, ESPP) but face risks related to the company's ability to attract and retain key personnel and potential misconduct.
• Customers and patients could benefit from the development of new therapeutics for immune-mediated diseases (budoprutug, CLYM116) addressing unmet medical needs, but also face risks of adverse events or side effects from product candidates.
• Suppliers and manufacturers, particularly single-source providers, are critical to the company's operations, and any disruptions could impact development timelines and costs.
• Creditors may face increased risk due to the company's recurring losses and ongoing need for substantial future financing.
• Regulatory bodies maintain oversight, and the company's compliance with evolving healthcare laws, data privacy regulations, and internal control requirements is crucial to avoid sanctions and maintain operational integrity.

Next Steps

• Dose the first patient in the Phase 2 PrisMN clinical trial of budoprutug in pMN in the coming weeks.
• Continue to pursue regulatory clearance to open additional budoprutug pMN trial sites outside the United States.
• Continue to activate sites and enroll and dose patients in the Phase 1b/2a clinical trial of budoprutug in ITP.
• Continue to activate sites and enroll and dose patients in the Phase 1b clinical trial of budoprutug in SLE.
• Actively enroll and dose subjects in the Phase 1 clinical trial of the SC formulation of budoprutug in Australia, with initial clinical data expected in the first half of 2026.
• Dose the first subject in the Phase 1 clinical trial of CLYM116 in Australia by year-end 2025, with initial clinical data anticipated in mid-2026.
• Evaluate the Kv7 program, including seeking a partner for further development.
• Remediate the identified material weaknesses in internal control over financial reporting.
• Potentially raise additional capital through equity offerings, debt financings, collaborations, or other strategic arrangements.
• Monitor and comply with evolving regulatory requirements, including those related to drug pricing and data privacy.

Key Dates

Recommendation

Climb Bio is advancing multiple promising product candidates, budoprutug and CLYM116, in immune-mediated diseases, with several clinical trials underway and positive preclinical data reported. The company also has an estimated cash runway through 2027, providing some operational stability. However, the company continues to incur substantial net losses and has not yet generated product revenue, which is typical for a clinical-stage biotech but highlights ongoing financial risk. The persistent material weaknesses in internal control over financial reporting are a significant governance concern that needs to be addressed. Given the mixed signals of strong pipeline progress against ongoing financial and operational risks, a 'Hold' recommendation is appropriate for investors to monitor further clinical trial results and the company's progress in remediating its internal control deficiencies before making a more definitive investment decision.

Keywords

Biotechnology, Clinical-stage, Immune-mediated diseases, Budoprutug, CLYM116, Primary membranous nephropathy, Immune thrombocytopenia, Systemic lupus erythematosus, Immunoglobulin A nephropathy, Monoclonal antibody, Anti-CD19, Anti-APRIL, Clinical trials, Drug development, SEC filing, 10-Q, Financial results, Biopharmaceutical, Orphan drug, Intellectual property, Corporate governance, Risk management